Open Nav

Diacarta Inc

  • Lydia Meyer-Turkson, DiaCarta Inc

Co-Development Partnerships

  • Date:Thursday, October 18
  • Time:9:30 AM - 9:45 AM
  • Room:Elizabethan C
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:Redefining Precision Molecular Diagnostics DiaCarta is a translational genomics and personalized diagnostics company that provides ultra-sensitive detection tools for cancer diagnosis, therapy identification and prognosis monitoring. Our mission is to provide ultra-sensitive and advanced technologies that will redefine the way molecular diagnostics and translational genomics impact healthcare treatment plans and the well-being of individuals around the world.
  • Company Website:http://www.diacarta.com/
  • Company HQ City:Richmond
  • Company HQ Country:United States
  • Company HQ State:California                  
  • CEO/Top Company Official:Dr Aiguo Zhang
  • Year Founded:2011
  • Main Therapeutic Focus:Diagnostics
  • Lead Product in Development :QuantiDNA RadTox Assay System -measuring radiation Toxicity using circulating DNA
  • Development Phase of Primary Product:Discovery
  • Number Of Unlicensed Products (For Which You Are Seeking Partners) :One
  • Additional Information/Comments:The QuantiDNA™ RadTox System is a unique, patented technology that measures tissue damage shortly following injury using cell-free DNA from a drop of blood. Premised on murine and primate studies showing that circulating DNA is logarithmically increased with whole-body radiation dose, RadTox has the potential to overcome many of the species-specific challenges faced by biomarker panels. Assay validation was completed in a Phase I SBIR with clinical trial samples from prostate cancer patients comparing RadTox to the current gold standard for toxicity prediction, the dose-volume histogram. Further research in a phase II SBIR Contract aims to complete a 500-patient, multi-institutional clinical trial evaluating the clinical utility of the test in patients treated with definitive radiotherapy for prostate cancer. DiaCarta seeks partnerships with X-Ray/Photon instrument manufacturers and healthcare diagnostic companies to codevelop the test to FDA approval and global launch.
  • Previous and Current Investors:Fortune Fountain Capital, Good Health Capital, BVCF
  • Size of Last Investment Round:$45,0000,000
  • Total Amount Raised to Date, In All Rounds:$53,000,000
Speakers
Lydia Meyer-Turkson
DiaCarta Inc
Back